This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
Patients voluntarily enrolled in this study by signing an informed consent form
Age ≥ 18 years
Signs of distant metastases other than peritoneal metastases at enrolment
Pregnant or breastfeeding women.
Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Eligible inpatients and outpatients from Ruijin Hospital
Other
Prospective
Not listed
Target-to-background ratio(TBR)
68Ga-FAPI and 18F-FDG uptake ratio of primary gastric lesions, peritoneal lesions and recurrent metastatic lesions to mediastinum and liver blood pool on PET/CT images.
Standardized uptake value(SUV)
SUV of 68Ga-FAPI and 18F-FDG uptake on PET/CT images for primary gastric lesions, peritoneal lesions and recurrent metastatic lesions
Evaluation the outcome of conversion therapy
The value of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in evaluating the outcome of conversion therapy in gastric cancer with peritoneal metastasis.
Progress free survival
Progress free survival
Overall survival
Overall survival
Click on the lead sponsor to view all of their trials.
